Skip to content

Effect of Noninvasive Ventilation on Lung Function in Amyotrophic Lateral Sclerosis

Effect of Noninvasive Positive Pressure Ventilation on Pulmonary Function Testing in Amyotrophic Lateral Sclerosis

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00537446
Enrollment
8
Registered
2007-10-01
Start date
2007-09-30
Completion date
2012-08-31
Last updated
2020-11-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Amyotrophic Lateral Sclerosis, Motor Neuron Disease

Keywords

noninvasive ventilation

Brief summary

Amyotrophic Lateral Sclerosis (ALS), or Lou Gehrig's Disease, is a fatal disorder that causes progressive degeneration and weakening of the muscles of breathing, leading to breathing insufficiency and eventually breathing failure. This breathing insufficiency is commonly treated with a breathing assistance device, known as noninvasive positive pressure ventilation (NIPPV). While generally well tolerated and accepted, it is not clear whether or to what extent NIPPV in fact helps breathing function: some data suggest that NIPPV preserves breathing function over time, whereas other data suggest that it actually causes breathing function to decline more quickly. No studies have shown what the acute effect of NIPPV is on breathing muscle function in ALS patients. This study will test the hypothesis that the acute use of NIPPV, at pressure levels that are in common clinical use, will cause measurable changes in tests of breathing function, compared to baseline and to lower levels of NIPPV. We expect that the results of this study will help to clarify whether and to what extent NIPPV assists respiratory muscle function in patients with ALS.

Interventions

Each subject will undergo 2 hours of high-level noninvasive positive pressure ventilation, with an inspiratory positive airway pressure of 12 cm H2O and an expiratory positive airway pressure of 3 cm H2O.

Sponsors

Columbia University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
SUPPORTIVE_CARE
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* clinical diagnosis of amyotrophic lateral sclerosis * clinical indication to start noninvasive ventilation (forced vital capacity \< 50% predicted or signs/symptoms of respiratory insufficiency) * age 18 to 80 years old

Exclusion criteria

* prior institution of NIPPV * inability to safely use NIPPV * indications for tracheostomy assisted ventilation because of inability to clear secretions from the airway * inability or unwillingness to perform pulmonary function testing * presence of advanced dementia.

Design outcomes

Primary

MeasureTime frame
Difference in Pulmonary Function and Respiratory Muscle Pressure Testing5 hours
Difference in Gas Exchange5 hours
Difference in Subjective Dyspnea Between Baseline and the Two Different Ventilator Modes5 hours

Countries

United States

Participant flow

Participants by arm

ArmCount
High Level and Low Level Ventilation
All participants
8
Total8

Baseline characteristics

CharacteristicHigh Level and Low Level Ventilation
Age, Categorical
<=18 years
0 Participants
Age, Categorical
>=65 years
1 Participants
Age, Categorical
Between 18 and 65 years
7 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
1 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
7 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
Region of Enrollment
United States
8 participants
Sex: Female, Male
Female
3 Participants
Sex: Female, Male
Male
5 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 80 / 8
other
Total, other adverse events
0 / 80 / 8
serious
Total, serious adverse events
0 / 80 / 8

Outcome results

Primary

Difference in Gas Exchange

Time frame: 5 hours

Population: Data were collected but not analyzed as specified in the title because the sample size does not generate enough statistical significance. PI no longer has raw data on file. All efforts have been made to retrieve the data and data could not be recovered.

Primary

Difference in Pulmonary Function and Respiratory Muscle Pressure Testing

Time frame: 5 hours

Population: Data were collected but not analyzed as specified in the title because the sample size does not generate enough statistical significance. PI no longer has raw data on file. All efforts have been made to retrieve the data and data could not be recovered.

Primary

Difference in Subjective Dyspnea Between Baseline and the Two Different Ventilator Modes

Time frame: 5 hours

Population: Data were collected but not analyzed as specified in the title because the sample size does not generate enough statistical significance. PI no longer has raw data on file. All efforts have been made to retrieve the data and data could not be recovered.

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026